ERP Biomarkers of Cognitive Dysfunction in Alzheimer’s Disease: Real-World Evidence Supporting Translational Clinical Trial Endpoints Advances in neuroscience and digital biomarkers are transforming how clinicians and researchers detect, monitor, and study Alzheimer’s disease (AD). At the 2025 Clinical Trials on…
The Hawaii ALS and Neuromuscular Center has been selected to participate in the ADAPT-EARLY clinical trial, a Phase 4 research study evaluating efgartigimod PH20 SC in adults with new-onset generalized myasthenia gravis (gMG). This important study focuses on early treatment…
